Long Acting Muscarinic Antagonist (lama) For Copd Therapeutics
1. Tudorza Pressair patent expiration
Treatment: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic obstructive pulmonary disease (copd); Treatment of a respiratory di...
TUDORZA PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(9 years ago) | |
| US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(5 years ago) | |
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(9 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(3 years ago) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
| M(M-256) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Dosage: POWDER, METERED
More Information on Dosage
TUDORZA PRESSAIR family patents
2. Yupelri patent expiration
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US11858898 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(5 years from now) | |
| US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Oct, 2028
(2 years from now) | |
| US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11484531 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Oct, 2039
(13 years from now) | |
| US12285417 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Aug, 2039
(13 years from now) | |
| US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US12048692 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Aug, 2039
(13 years from now) | |
| US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| US11691948 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(4 years from now) | |
| US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Dosage: SOLUTION
How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage
YUPELRI family patents